Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Maziarz, Richard T., Waller, Edmund K., Jaeger, Ulrich, Fleury, Isabelle, McGuirk, Joseph, Holte, Harald, Jaglowski, Samantha, Schuster, Stephen J., Bishop, Michael R., Westin, Jason R., Mielke, Stephan, Teshima, Takanori, Bachanova, Veronika, Foley, Stephen R., Borchmann, Peter, Salles, Gilles A., Zhang, Jie, Tiwari, Ranjan, Pacaud, Lida B., Ma, Qiufei, Tam, Constantine S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2020
Teme:
Immunobiology and Immunotherapy
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042998/
https://ncbi.nlm.nih.gov/pubmed/32074277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001026
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki